This is one of a series of papers arising in part. out of the SHARE (Supporting and structuring Healthgrid Activities and Research in Europe) project;' in previous work, we have examined the use of integrated care pathways (ICPs), a fine-grained form of medical guideline including the explicit recording of any deviation, or 'variance', for research purposes. In particular, we explored how feeding the results of the analysis of variance into the development of a pathway might be an effective way of capturing 'evidence from practice'.
With electronic care pathways (elCPs or ECPs) and the electronic health record (EHR) both being advanced as enhanced sources of data for research purposes, an area of interest here would be how data from both could be intelligently integrated. An example of how this might be performed emerged through our work on the EuroPGDCode project.
PGD and PGS are treatments for patients who have or are carriers of an inherited genetic disorder, which might be a chromosomal abnormality or genetic mutation, and which could imply a serious health risk for any children they have. They are conducted alongside assisted reproduction, such as in vitro fertilization or intracytoplasmic sperm injections. In order to gather more information about the efficacy of PGD and PGS, members of the project based at Guy's Hospital, London produced a paediatric follow-up questionnaire, which was circulated to centres around the world. They have entered data into a system designed by project members at the University of the West of England, Bristol.
Although at an early stage, questions have already emerged:
• Did the parents have any medical conditions either related or unrelated to the genetic condition in their family? Where an abnormality was picked up in a child, is this something that had been seen in either parent previously? Could it be prevalent in that family (i.e, asthma)? • Where there were obstetric complications during the birth of a PGD baby, had this occurred in previous pregnancies for that couple? For example, in relation to prematurity or intra-uterine growth retardation, is this something common to the family? • Did the patients have a choice of suitable embryos at the point where embryos were transferred? Where there was no choice of embryo, to what extent is it more likely that the children born from these PGD cycles would have abnormalities or health problems?
While other questions could be answered by using data collected via the questionnaire, these questions require more information about the patients and previous periods of care. What would be needed is a way of extracting the relevant pieces of data from records that correspond to those previous episodes of care -this is what we will now propose. The centralized PGD database would serve as a starting point, allowing the researcher to formulate their questions, perform exploratory queries and identify patients of interest. All records held in the database are pseudonymized. The next step is to identify which ICPs have been involved, and contain data of interest to the researcher. The patient identifiers and ICP identifiers are then sent to the distributed centres, requesting the data for those patents. For each ICp, an ontology would have been previously defined. In Where the ICP in use is recognized, data must now be extracted from the ICP record. Using an ontology to aid in this extraction allows for some variation between ICPs, rather than a formal model approach that would be less flexible. For example, Daniyal et al. s demonstrated how location-specific pathways could be unified by using an ontology for prostate cancer pathways. When extracted, the data are then pseudonymized and sent back. An example of relevant variance following the delivery of a PGD baby can be seen in Figure 1 . Where the data are held in an EHR rather than a recognized ICp, an attempt must be made to match the record to an ICP. A branching care pathway or guldeline for a specific diagnosed condition could be expressed as a series of possible paths, each with anchor points such as referrals or key test results. The EHR could be mined for these anchor points, which may correspond to periods where a patient's care followed a particular guideline or pathway. The details between the anchor points can then be analysed to determine whether any variance was likely; at a basic level, the length of time between anchor points could be a good indication that the course of care may not have been as predicted. The original pathway would then be augmented with comments to indicate where complications are likely, further branching might be beneficial, etc. The formalization of the guideline or pathway would be a prerequisite for this approach, with PROforma being one example of a formal guideline modelling language; Seyfang et al. 6 have reported some success in easing the conversion via an intermediate ontology.
Where a match is made, the care pathway ontology would be employed to extract the relevant data. In order to conduct a case-control study, records for controls could also be selected in a similar way at each site.
As mentioned above, we are also looking at the possibility of using an ontology of drug interactions to help with situations where patients are following multiple ICPs, and the combination of drugs which might lead to adverse reactions. Examples already exist where ontologies have been employed to identify possible problems with drug interactions, but these are seen to be limited to simple notification of the potential problem." Formal guideline modelling, using PRODIGY or PROforma for example, can include components for drug selection accounting for interactions and contraindications, and based on previous use." Using existing data on drug interactions, such as those collected by the British National Formulary, ontology-based reasoning could also look at the severity and nature of the interaction. Where variance data include the selection of alternative drugs, and is linked to an outcome, such data could also be utilized.
Grid or cloud computing is essentially an evolution of distributed computing, where many computers are used in parallel, perhaps over many sites, some for storage, some for processing, etc. The use of a grid or cloud would seem to be a logical approach here, given in part that the ICP data are distributed, ICPs (and control over them) vary at a local level and the potentially computationally intensive task of extracting the required data. As the data involved are in part from ICP records, the subsequent analysis could also include the identification of missing data of interest that could be collected (either in the form of coded variance, or additional items that should be recorded), and any branches in the pathway that might be beneficial. ••...........................................•.•........... ...
Conclusion
The system outlined above involves integrating information in a variety of forms: retrospective and audit data collected via the questionnaire and stored in a central repository, highly structured and fine-grained data from care pathways and stored at remote sites, and the semi-structured notes of an EHR (albeit mapped to a care pathway). The sensitive nature of the data requires extensive pseudonymization, which may not be trivial given the level of details involved.
Our previous work involved examining ICPs as vehicles for conducting research and collecting 'evidence from practice' in the form of variance records. This paper highlights another example of how ICPs might be exploited for research purposes, and how data from both ICPs and EHRs might be intelligently combined through a process involving the mapping of EHR data onto an ICP model, and the use of an ontology to aid in the subsequent extraction of that data. The use of generic care pathway ontologies rather than specific PGD ontologies means this approach has fairly wide applicability.
